{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T07:12:08Z","timestamp":1649833928196},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,7,20]],"date-time":"2014-07-20T00:00:00Z","timestamp":1405814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00280-014-2533-6","type":"journal-article","created":{"date-parts":[[2014,7,19]],"date-time":"2014-07-19T13:58:44Z","timestamp":1405778324000},"page":"427-432","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia"],"prefix":"10.1007","volume":"74","author":[{"given":"Aleksandar","family":"Radujkovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Luft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Jens Zeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Fruehauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Topaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,20]]},"reference":[{"key":"2533_CR1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330\u20131340","journal-title":"N Engl J Med"},{"key":"2533_CR2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, M\u00fcller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sau\u00dfele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"2533_CR3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon FX, Blakesley RE, Gallagher NJ, Gillis K, Goldberg SL, Larson RA, Hochhaus A, Ottmann OG (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959\u2013962","journal-title":"Leukemia"},{"key":"2533_CR4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","volume":"47","author":"J Radich","year":"2010","unstructured":"Radich J (2010) Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol 47:354\u2013361","journal-title":"Semin Hematol"},{"key":"2533_CR5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.leu.2402041","volume":"15","author":"J Topaly","year":"2001","unstructured":"Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342\u2013347","journal-title":"Leukemia"},{"key":"2533_CR6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.bjc.6600242","volume":"86","author":"J Topaly","year":"2002","unstructured":"Topaly J, Fruehauf S, Ho AD, Zeller WJ (2002) Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 86:1487\u20131493","journal-title":"Br J Cancer"},{"key":"2533_CR7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","volume":"97","author":"Y Kano","year":"2001","unstructured":"Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999\u20132007","journal-title":"Blood"},{"key":"2533_CR8","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","volume":"19","author":"A Radujkovic","year":"2005","unstructured":"Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ (2005) Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL\u2013Inhibition of P-glycoprotein function by 17-AAG. Leukemia 19:1198\u20131206","journal-title":"Leukemia"},{"key":"2533_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"2533_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2141.2002.03806.x","volume":"119","author":"J Topaly","year":"2002","unstructured":"Topaly J, Zeller WJ, Fruehauf S (2002) Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 119:3\u201314","journal-title":"Br J Haematol"},{"key":"2533_CR11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/10428190802517765","volume":"50","author":"MG Martin","year":"2009","unstructured":"Martin MG, Dipersio JF, Uy GL (2009) Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leuk Lymphoma 50:14\u201323","journal-title":"Leuk Lymphoma"},{"key":"2533_CR12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1600-0609.2011.01689.x","volume":"87","author":"S Vaidya","year":"2011","unstructured":"Vaidya S, Ghosh K, Vundinti BR (2011) Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 87:381\u2013393","journal-title":"Eur J Haematol"},{"key":"2533_CR13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST571: diverse mechanisms of resistance. Blood 96:1070\u20131079","journal-title":"Blood"},{"key":"2533_CR14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","volume":"68","author":"RA Larson","year":"2012","unstructured":"Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD (2012) Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph\u00a0+\u00a0chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68:723\u2013733","journal-title":"Eur J Clin Pharmacol"},{"key":"2533_CR15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/sj.bmt.1702236","volume":"25","author":"F Fauth","year":"2000","unstructured":"Fauth F, Martin H, Sonnhoff S, Bialleck H, Wiesneth M, Mihanovic B, Hoelzer D (2000) Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells. Bone Marrow Transplant 25:831\u2013836","journal-title":"Bone Marrow Transplant"},{"key":"2533_CR16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","volume":"13","author":"JS McCune","year":"2007","unstructured":"McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B, Schoch HG, McDonald GB (2007) Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 13:853\u2013862","journal-title":"Biol Blood Marrow Transplant"},{"key":"2533_CR17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","volume":"35","author":"DW Beelen","year":"2005","unstructured":"Beelen DW, Trenschel R, Casper J, Freund M, Hilger RA, Scheulen ME, Basara N, Fauser AA, Hertenstein B, Mylius HA, Baumgart J, Pichlmeier U, Hahn JR, Holler E (2005) Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant 35:233\u2013241","journal-title":"Bone Marrow Transplant"},{"key":"2533_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin RE (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8:145\u2013154","journal-title":"Biol Blood Marrow Transplant"},{"key":"2533_CR19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4161\/cbt.6.6.4101","volume":"6","author":"F Belloc","year":"2007","unstructured":"Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon FX (2007) Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther 6:912\u2013919","journal-title":"Cancer Biol Ther"},{"key":"2533_CR20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","volume":"110","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M (2007) Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110:340\u2013344","journal-title":"Cancer"},{"key":"2533_CR21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ejh.12289","volume":"92","author":"A Radujkovic","year":"2014","unstructured":"Radujkovic A, Dreger P, Hegenbart U, Buss EC, Luft T, Ho AD, Fruehauf S, Topaly J (2014) Imatinib-supplemented myeloablative total-body irradiation\/cyclophosphamide conditioning prior to allogeneic stem cell transplantation as consolidation treatment in patients with blast crisis of chronic myeloid leukemia. Eur J Haematol 92:546\u2013549","journal-title":"Eur J Haematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2533-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2533-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T12:14:29Z","timestamp":1598098469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2533-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,20]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2533"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2533-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,20]]}}}